According to Fortune Business Insights, the global next-generation sequencing (NGS) market size was valued at USD 10.44 billion in 2025 and is projected to grow from USD 11.79 billion in 2026 to USD 38.34 billion by 2034, exhibiting a CAGR of 15.88% during the forecast period. North America dominated the next-generation sequencing market with a market share of 56.01% in 2025.
The market is witnessing strong growth due to declining sequencing costs, increasing adoption of precision medicine, expanding applications in clinical diagnostics, rising investments in genomics research, and growing demand for personalized healthcare solutions. Technological advancements in sequencing platforms, bioinformatics tools, and data analytics are further accelerating market expansion.
Key Market Drivers
Increasing Adoption of Precision Medicine
Healthcare providers are increasingly utilizing genomic information to develop personalized treatment strategies, driving demand for NGS technologies.
Rising Prevalence of Genetic and Chronic Diseases
Growing incidence of cancer, cardiovascular disorders, rare genetic diseases, and inherited conditions is supporting the adoption of advanced sequencing solutions.
Expanding Genomics Research Activities
Government initiatives, academic research programs, and pharmaceutical investments in genomics are significantly contributing to market growth.
Market Restraints
High Data Analysis Complexity
The large volume of sequencing data generated by NGS platforms requires sophisticated bioinformatics tools and specialized expertise.
Regulatory and Reimbursement Challenges
Clinical adoption may be impacted by evolving regulatory requirements and reimbursement limitations in certain regions.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/next-generation-sequencing-ngs-market-101000
Market Opportunities
Growth of Clinical Sequencing Applications
Increasing use of NGS in oncology, reproductive health, infectious disease testing, and rare disease diagnostics is creating substantial growth opportunities.
Advancements in Long-Read and Real-Time Sequencing
Emerging sequencing technologies are improving accuracy, speed, and scalability, expanding the scope of genomic analysis.
Segmentation
By Type
Products
- Instruments
- Consumables
Services
By Technology
- Sequencing By Synthesis (SBS)
- Nanopore Sequencing
- ION Semiconductor Sequencing
- Others
By Application
Research & Applied
Clinical
- Cardiovascular
- Oncology
- Genetic Diseases
- Reproductive Health
By End-User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
Regional Insights
North America
North America dominated the NGS market with a share of 56.01% in 2025. The region benefits from advanced healthcare infrastructure, substantial investments in genomics research, strong presence of biotechnology companies, widespread adoption of precision medicine, and favorable funding for genomic initiatives.
Europe
Europe is witnessing significant growth due to increasing research collaborations, expanding genomic medicine programs, and rising adoption of advanced molecular diagnostics.
Asia Pacific
Asia Pacific is expected to register the fastest growth during the forecast period owing to increasing healthcare investments, expanding genomics research activities, growing biotechnology sectors, and rising demand for personalized medicine.
Rest of the World
Latin America and the Middle East & Africa are gradually increasing adoption of NGS technologies as healthcare systems modernize and genomic research capabilities expand.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/next-generation-sequencing-ngs-market-101000
Key Players in the Next-Generation Sequencing Market
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- QIAGEN N.V.
- Agilent Technologies, Inc.
- BGI Genomics Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- PerkinElmer, Inc.
- Danaher Corporation
Conclusion
The global next-generation sequencing market is expected to witness robust growth through 2034, driven by increasing adoption of precision medicine, expanding clinical applications, and growing investments in genomics research. Advancements in sequencing technologies, declining sequencing costs, and the increasing integration of genomics into healthcare and drug development are expected to create substantial growth opportunities for market participants during the forecast period.